BRCA Mutations in Latinas
NCT01251900
Breast Diseases, Breast Neoplasms
Lubbock, Texas, United States
View Trial DetailsNCT Number: NCT05478590
The study is descriptive and aims to characterize the treatment patterns of advanced breast cancer in Poland in the real-world data setting. The main goals are to assess the current treatment patterns of hormone receptor-positive (HR+) Human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer and their changes in clinical practice and relate them to patients' demographics, disease characteristics, type of other therapies used in patients as well as disease progression and visceral crisis occurrence.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Ambulatorium Chemioterapii Centrum Onkologii, Bydgoszcz, Poland
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 01 September 2020 through 31 August 2021
Time frame: 01 September 2020 through 31 August 2021
Time frame: 01 September 2020 through 31 August 2021
Time frame: 01 September 2020 through 31 August 2021
Time frame: 01 September 2020 through 31 August 2021
Time frame: 01 September 2020 through 31 August 2021
Time frame: 01 September 2020 through 31 August 2021
Time frame: 01 September 2020 through 31 August 2021
In this outcome measure participants with different treatment modalities including hormonotherapy and chemotherapy
Time frame: 01 September 2020 through 31 August 2021
In this outcome measure participants with different treatment modalities including hormonotherapy and chemotherapy
Time frame: 01 September 2020 through 31 August 2021
Last Dose of Last Drug Taken in Adjuvant Treatment
Time frame: 01 September 2020 through 31 August 2021
Time frame: 01 September 2020 through 31 August 2021
Time frame: 01 September 2020 through 31 August 2021
Time frame: 01 September 2020 through 31 August 2021
Time frame: 01 September 2020 through 31 August 2021
Time frame: 01 September 2020 through 31 August 2021
Time frame: 01 September 2020 through 31 August 2021
Time frame: 01 September 2020 through 31 August 2021
ABC5 guideline definition visceral crisis (updated in 2020) is a severe organ disfunction that involve: Severe symptoms and signs, rapid disease progression, and laboratory values
Pfizer
Industry
HR POSITIVE, HER 2 NEGATIVE ADVANCED BREAST CANCER- TREATMENT PATTERNS IN POLAND - HABER STUDY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01251900
Breast Diseases, Breast Neoplasms
Lubbock, Texas, United States
View Trial DetailsNCT03314688
Breast Diseases, Breast Neoplasms
New Haven, Connecticut, United States
View Trial DetailsNCT04572295
Acrocephalosyndactylia, Bone Diseases
Nagoya, Aichi-ken, Japan
View Trial DetailsNCT07096024
Breast Diseases, Breast Neoplasms
New York, United States
View Trial Details